Prazosin therapy for refractory variant angina

Dan Tzivoni*, Andre Keren, Jesaia Benhorin, Shmuel Gottlieb, Daphna Atlas, Shlomo Stern

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


The selective alpha1 blocker prazosin was used to abolish Prinzmetal's variant angina in six patients. All had had an acute transmural myocardial infarction, after which the anginal attacks with transient ST segment elevation developed, and three of them had already suffered from variant angina prior to the infarction. Therapeutic trials with high doses of nifedipine, verapamil, nitrates, beta blockers, and (in one case) phenoxybenzamine were ineffective in all six patients. Prazosin, 8 to 30 mg/day, combined with low-dose nitrates or nifedipine completely abolished the attacks in four patients, markedly reduced their frequency and intensity in one patient, and had to be stopped in the sixth one because of hypotension and dizziness. Except for this last patient, the drug was well tolerated by all the others, and no changes in blood pressure were observed. In four patients discontinuation or reduction of prazosin resulted in exacerbation of symptoms, but its renewal was followed by disappearance of the attacks. Since the mean follow-up period in this study was 4 to 6 months, further evaluation appears necessary concerning the long-term effects of this drug in Prinzmetal's variant angina.

Original languageEnglish
Pages (from-to)262-266
Number of pages5
JournalAmerican Heart Journal
Issue number2
StatePublished - Feb 1983
Externally publishedYes


Dive into the research topics of 'Prazosin therapy for refractory variant angina'. Together they form a unique fingerprint.

Cite this